- Home
- WIW vs ALT Comparison
WIW vs ALT Comparison
Compare WIW & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WIW | ALT |
|---|---|---|
| Founded | 2004 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 519.5M | 421.5M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | WIW | ALT |
|---|---|---|
| Price | $8.51 | $3.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 217.4K | ★ 3.1M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 11.14% | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $8.33 | $2.56 |
| 52 Week High | $9.03 | $7.73 |
Technical Indicators
Market Signals| Indicator | WIW | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 50.60 | 51.76 |
| Support Level | $8.34 | $2.87 |
| Resistance Level | $8.62 | $3.26 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 68.18 | 67.00 |
Price Performance
Historical ComparisonAbout WIW Western Asset Inflation-Linked Opportunities & Income Fund
Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income. Capital appreciation, when consistent with current income, is a secondary investment objective. The fund operates as a single operating segment, which is an investment portfolio.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.